Total Knee Arthroplasty (TKA) Study of HTX-011 in an Multimodal Analgesic Regimen (MMA) Regimen

Phase 3

Completed

• Conditions: Analgesia
• Interventions: Drug: HTX-011; Drug: Ibuprofen; Drug: Acetaminophen; Drug: +/- Bupivacaine HCl; Drug: Celecoxib; Device: Luer Lock Applicator

• Registration Number: NCT03974932
• Lead Sponsor: Heron Therapeutics

Brief Summary

Phase 3b, open-label single-arm study in which all subjects receive HTX-011 as part of a scheduled non-opioid MMA regimen.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-06-03
• Study First Submitted QC: 2019-06-03
• Study Start: 2019-06-05
• Study First Posted: 2019-06-05
• Primary Completion: 2020-12-07
• Study Completion: 2021-01-07
• Results First Submitted: 2021-12-17
• Status Verified: 2023-08
• Results First Submitted QC: 2023-08-08
• Last Update Submitted: 2023-08-08
• Results First Posted: 2023-08-31
• Last Update Posted: 2023-08-31

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 116

Inclusion Criteria

• Is scheduled to undergo primary unilateral TKA under spinal anesthesia.
• Has not previously undergone TKA in either knee.
• Has an American Society of Anesthesiologists (ASA) Physical Status of I, II, or III.
• Is able to walk at least 20 feet with optional use of a 4-legged walker for balance.
• Female subjects are eligible only if not pregnant, not lactating, not planning to become pregnant during the study, sterile; or is at least 2 years post-menopausal; or is in a monogamous relationship with a partner who is surgically sterile; or using acceptable contraceptives.

Read More

Exclusion Criteria

• Has a planned concurrent surgical procedure.
• Has other pre-existing concurrent acute or chronic painful physical/restrictive condition expected to require analgesic treatment in the postoperative period for pain.
• Has a contraindication or a known or suspected history of hypersensitivity or clinically significant idiosyncratic reaction to required study medications.
• Using or expected to use Factor IX Complex or anti-inhibitor coagulant concentrates during the study.
• Has known or suspected daily use of opioids for 7 or more consecutive days within the previous 6 months.
• Has taken NSAIDs within 10 days prior to the scheduled surgery with the exception of subjects on low-dose (≤100 mg) daily acetylsalicylic acid for cardioprotection.
• Has taken opioids within 24 hours prior to the scheduled surgery (3 days for long-acting).
• Has been administered bupivacaine within 5 days prior to the scheduled surgery.
• Has been administered any local anesthetic within 72 hours prior to the scheduled surgery.
• Has initiated treatment with medications within 1 month prior to study drug administration that can impact pain control.
• Has been administered systemic steroids within 5 half-lives or 10 days prior to administration of study drug.
• Received an investigational product or device in a clinical trial within 30 days or within 5 elimination half lives.
• Has a known or suspected history of drug abuse, a positive drug screen on the day of surgery, or a recent history of alcohol abuse.
• Has a medical condition such that, in the opinion of the Investigator, participating in the study would pose a health risk to the subject or confound the postoperative assessments.
• Is currently undergoing treatment for hepatitis B, hepatitis C, or HIV.
• Has uncontrolled anxiety, psychiatric, or neurological disorder that, in the opinion of the Investigator, might interfere with study assessments.
• Has acquired defective color vision or acute gastrointestinal ulcers, either of which could interfere with scheduled study medications.
• Has any chronic neuromuscular deficit of either femoral nerve function or thigh musculature.
• Has any chronic condition or disease that would compromise neurological or vascular assessments.
• Had a malignancy in the last year, with the exception of nonmetastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.
• Has undergone 3 or more surgeries within 12 months.
• Has a body mass index (BMI) >39 kg/m2.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Cohort 3	+/- Bupivacaine HCl	HTX-011 + MMA
Cohort 4	HTX-011	HTX-011 + MMA
Cohort 1	HTX-011	HTX-011 + MMA
Cohort 1	Celecoxib	HTX-011 + MMA
Cohort 2	HTX-011	HTX-011 + MMA
Cohort 1	Luer Lock Applicator	HTX-011 + MMA
Cohort 2	Luer Lock Applicator	HTX-011 + MMA
Cohort 3	Luer Lock Applicator	HTX-011 + MMA
Cohort 3	HTX-011	HTX-011 + MMA
Cohort 4	Luer Lock Applicator	HTX-011 + MMA
Cohort 4	Acetaminophen	HTX-011 + MMA
Cohort 1	Acetaminophen	HTX-011 + MMA
Cohort 1	Ibuprofen	HTX-011 + MMA
Cohort 2	Ibuprofen	HTX-011 + MMA
Cohort 2	Acetaminophen	HTX-011 + MMA
Cohort 2	Celecoxib	HTX-011 + MMA
Cohort 3	Ibuprofen	HTX-011 + MMA
Cohort 3	Acetaminophen	HTX-011 + MMA
Cohort 3	Celecoxib	HTX-011 + MMA
Cohort 4	Ibuprofen	HTX-011 + MMA

Primary Outcome Measures

Name	Time	Method
Mean Area Under the Curve (AUC) of the Visual Analogue Scale (VAS).	12 through 48 hours	The Visual Analog Scale (VAS) consists of a straight 10-cm line that represents pain ranging from "no pain" to "pain as bad as it could be". Subjects were asked to mark their current pain level on the line.

Secondary Outcome Measures

Name	Time	Method
Maximum Concentration (Cmax)	72 hours
Mean AUC of the NRS of Pain Intensity at Rest (NRS-R).	72 hours	Pain intensity scores are assessed using an 11-point Numeric Rating Scale (NRS) (0-10) where 0 represents "no pain" and 10 represents "worst pain". NRS scores are measured at rest.
Percentage of Subjects Who Are Opioid-free	72 Hours to Day 11
Median Time to First Opioid Rescue Medication.	Through 72 hours
Mean Total Postoperative Opioid Consumption (in IV Morphine Milligram Equivalents [MME]).	72 hours
Percentage of Subjects Who Are Opioid-free Through 72 Hours Who Remain Opioid-free Through Day 11.	72 hours through Day 11
Median Time to First Ambulation Postsurgery.	72 hours
Percentage of Subjects With Severe Pain.	24 hours, 48 hours, 72 hours	Severe Pain defined as a VAS score ≥7.5 cm.
Percentage of Subjects Who do Not Receive an Opioid Prescription Between Discharge and the Day 11 Visit.	72 hours through Day 11
Percentage of Subjects Achieving a Score of "Good" or Better (>1) Pain Control Based on Patient Global Assessment (PGA).	24 hours, 48 hours, 72 hours, Day 11	Patient's Global Assessment (PGA) of pain control is a 4-point scale in which subjects rate how well their pain has been controlled (0 = Poor; 1 = Fair; 2 = Good; 3 = Excellent).
Percentage of Subjects Who do Not Receive an Opioid Prescription at Discharge.	72 hours
Mean AUC of VAS Scores.	72 hours	The Visual Analog Scale (VAS) consists of a straight 10-cm line that represents pain ranging from "no pain" to "pain as bad as it could be". Subjects were asked to mark their current pain level on the line.
Percentage of Subjects Who First Achieve an MPADSS Score ≥9.	2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24, hours, 36 hours, 48 hours, 60 hours, 72 hours	Subjects were assessed for readiness for discharge using the Modified Post-Anesthesia Discharge Scoring System (MPADSS) that assesses 5 clinical variables: vital signs, ambulation, nausea/vomiting, pain, and surgical bleeding, each on a 3-point scale of 0, 1, or 2 with 0 being the worst score and 2 being the best score. Subjects with an MPADSS score of 9 or 10 were considered ready for discharge.
Percentage of Subjects Who Are Discharged Home vs to a Skilled Nursing Facility.	72 hours	Number Analyzed represents Subjects who were discharged home.
Mean Overall Benefit of Analgesia Score (OBAS).	24 hours, 48 hours, 72 hours, Day 11	Subjects were questioned about their overall benefit of analgesia. Overall benefit of analgesia score (OBAS) assesses current pain at rest, vomiting, itching, sweating, freezing, dizziness, and overall satisfaction with postoperative pain during the previous 24 hours. To calculate the OBAS score, each of the subscale scores (0=minimum; 4=maximum) are summed for a combined OBAS score. Possible scores could range from 0 to 28 with a lower score indicating greater benefit.
Mean Total TSQM-9 Score	72 hours through Day 11	The Treatment Satisfaction Questionnaire for Medication (TSQM-9) contains 9 items assessing Effectiveness, Convenience, and Global Satisfaction domains. Responses to items are rated on a 5-point or 7-point rating scale. Scores for each domain are computed by adding the TSQM items in each domain and then transforming the values in to a composite score ranging from 0 to 100, with higher scores representing higher satisfaction.
Time of Occurrence of Maximum Concentration (Tmax)	72 hours
Percentage of Subjects Unable to Participate in Each Rehabilitation Session Because of Pain.	72 hours

Trial Locations

Locations (6)

Endeavor Clinical Trials, LLC.; 🇺🇸 San Antonio, Texas, United States

Helen Keller Hospital; 🇺🇸 Sheffield, Alabama, United States

Phoenix Clinical Research, LLC; 🇺🇸 Tamarac, Florida, United States

Midwest Clinical Research Center, LLC; 🇺🇸 Dayton, Ohio, United States

First Surgical Hospital; 🇺🇸 Bellaire, Texas, United States

Plano Surgical Hospital; 🇺🇸 Plano, Texas, United States